NR4A1 and renal carcinoma: To date, mTORIs have been introduced into the therapy of several cancers: renal cancers, mantle cell lymphomas, advanced breast cancers (hormone receptor-positive), pancreatic, gastrointestinal, pulmonary neuroendocrine cancers, and sporadic lymphangiomatosis.